Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)

Li, JR; Cheng, YJ; Bai, CM; Xu, JM; Shen, L; Li, J; Zhou, ZW; Li, ZP; Chi, YHBL; Yu, XJ; Li, EX; Xu, N; Liu, TS; Lou, WH; Bai, YX; Yuan, XL; Wang, XW; Yuan, Y; Chen, J; Guan, S; Fan, SH; Su, WG

EUROPEAN JOURNAL OF CANCER, 2022; 169 (): 1

Abstract

Aim: To investigate the health-related quality of life (HRQoL) of patients who had neuroendocrine tumors (NETs) from SANET trials. Methods: Eligible p......

Full Text Link